Jason Shafrin
Jason Shafrin
FTI Consulting, Center for Healthcare Economics and Policy
Verified email at fticonsulting.com - Homepage
Title
Cited by
Cited by
Year
Estimated prevalence of undiagnosed atrial fibrillation in the United States
MP Turakhia, J Shafrin, K Bognar, J Trocio, Y Abdulsattar, D Wiederkehr, ...
PloS one 13 (4), e0195088, 2018
722018
Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States
MP Turakhia, J Shafrin, K Bognar, DP Goldman, PM Mendys, ...
The American journal of cardiology 116 (5), 733-739, 2015
682015
Operating on commission: analyzing how physician financial incentives affect surgery rates
J Shafrin
Health economics 19 (5), 562-580, 2010
682010
Utility of cancer value frameworks for patients, payers, and physicians
A Chandra, J Shafrin, R Dhawan
Jama 315 (19), 2069-2070, 2016
672016
Predicting real-world effectiveness of cancer therapies using overall survival and progression-free survival from clinical trials: empirical evidence for the ASCO value framework
DN Lakdawalla, J Shafrin, N Hou, D Peneva, S Vine, J Park, J Zhang, ...
Value in Health 20 (7), 866-875, 2017
442017
Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains
D Lakdawalla, J Shafrin, C Lucarelli, S Nicholson, ZM Khan, TJ Philipson
Health Affairs 34 (4), 555-561, 2015
352015
The association between observed mobility and quality of life in the near elderly
J Shafrin, J Sullivan, DP Goldman, TM Gill
PloS one 12 (8), e0182920, 2017
292017
Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia
JP MacEwan, FM Forma, J Shafrin, A Hatch, DN Lakdawalla, ...
Journal of managed care & specialty pharmacy 22 (11), 1349-1361, 2016
272016
Geographic variation in spending, utilization and quality: Medicare and Medicaid beneficiaries
T MaCurdy, J Bhattacharya, D Perlroth, J Shafrin, A Au-Yeung, H Bashour, ...
accessed on August 25, 2013, 2013
242013
Patient versus physician valuation of durable survival gains: implications for value framework assessments
J Shafrin, TT Schwartz, T Okoro, JA Romley
Value in Health 20 (2), 217-223, 2017
222017
A flexible open-source decision model for value assessment of biologic treatment for rheumatoid arthritis
D Incerti, JR Curtis, J Shafrin, DN Lakdawalla, JP Jansen
Pharmacoeconomics 37 (6), 829-843, 2019
172019
The economic burden of ACPA-positive status among patients with rheumatoid arthritis
J Shafrin, MG Tebeka, K Price, C Patel, K Michaud
Journal of managed care & specialty pharmacy 24 (1), 4-11, 2018
152018
Long-term health and economic value of improved mobility among older adults in the United States
M Kabiri, M Brauer, J Shafrin, J Sullivan, TM Gill, DP Goldman
Value in Health 21 (7), 792-798, 2018
142018
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: does …
J Shafrin, M Skornicki, M Brauer, J Villeneuve, M Lees, N Hertel, ...
Health Policy 122 (6), 607-613, 2018
132018
Physician and patient preferences for nonvalvular atrial fibrillation therapies
J Shafrin, A Bruno, JP MacEwan, A Campinha-Bacote, J Trocio, M Shah, ...
Value in Health 19 (4), 451-459, 2016
132016
Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers
J Shafrin, SG May, A Shrestha, C Ruetsch, N Gerlanc, F Forma, A Hatch, ...
Patient preference and adherence 11, 1071, 2017
122017
The cost of adherence mismeasurement in serious mental illness: a claims-based analysis
J Shafrin, F Forma, E Scherer, A Hatch, E Vytlacil, D Lakdawalla
Am J Manag Care 23 (5), e156-e163, 2017
112017
Geographic variation in the quality and cost of care for patients with rheumatoid arthritis
J Shafrin, A Ganguli, YS Gonzalez, JJ Shim, SA Seabury
Journal of managed care & specialty pharmacy 22 (12), 1472-1481, 2016
112016
Geographic Adjustment of Medicare Payments to Physicians: Evaluation of IOM Recommendations
T MaCurdy, J Shafrin, T DeLeire, J DeVaro, M Bounds, D Pham, A Chia
Washington, DC: Acumen LLC, 2012
112012
Estimating the value of new technologies that provide more accurate drug adherence information to providers for their patients with schizophrenia
J Shafrin, TT Schwartz, DN Lakdawalla, FM Forma
Journal of managed care & specialty pharmacy 22 (11), 1285-1291, 2016
82016
The system can't perform the operation now. Try again later.
Articles 1–20